| Tasimelteon | Vanda pharma | ||
| 4 mg/mL ; Suspension |
Less Than $1000 mn
|
||
|
Less Than 5
|
Less Than 5
|
||
| None |
Less Than 5
|
||
| None | None | ||
| HETLIOZ is a melatonin receptor agonist. HETLIOZ LQ oral suspension is indicated for the treatment of: • Nighttime sleep disturbances in SMS in pediatric patients 3 years to 15 years of age. | |||
|
Yes
| |||
| Hetlioz LQ | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 | Patent 13 | Patent 14 | Patent 15 | Patent 16 | Patent 17 | Patent 18 | Patent 19 | Patent 20 | Patent 21 | Patent 22 | Patent 23 | Patent 24 | Patent 25 | Patent 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| *** **** | *** ********* | *** ********* | **** ** *** **, **** | *** ********* | **** ** *** **, **** | *** ********* | **** ** *** **, **** | *** ********* | *** ********* | **** ** *** **, **** | *** ********* | *** ********* | **** ** *** **, **** | **** ** *** **, **** | **** ** *** **, **** | *** ********* | **** ** *** **, **** | *** ********* | *** ********* | *** ********* | *** ********* | **** ** *** **, **** | **** ** *** **, **** | *** ********* | **** ** *** **, **** (***** ******) | **** ** *** **, **** (***** ******) |
| ****** ******* ************** ***** *********** | ********* ** ********* ****** ********* | ****** ** ********* | ****** ** ********* | ********* ** ********* ****** ********* | ****** ** ********* | ****** ******** ************** ***** *********** | ********* ** ********* ****** ********* | ****** ** ********* | ****** *********** ************ *** ******* ** *** ******* | ****** ** ********* | ********* ** ********* ****** ********* | ****** ******** ************** ***** *********** | ********* ** ********* ****** ********* | ****** *********** ************ *** ******* ** *** ******* | ****** ******** ************** ***** *********** | ****** ** ********* | ********* ** ********* ****** ********* | ********* ** ********* ****** ********* | ********* ** ********* ****** ********* | ********* ** ********* ****** ********* | ********* ** ********* ****** ********* | ****** ******** ************** ***** *********** | ********* ** ********* ****** ********* | ********* ** ********* ****** ********* | ********* ** ********* ****** ********* |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| *** **** | *** \ ********* | *** **, **** | ******* | ********* ******** | *** ****** *** **** (***) |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|